228 related articles for article (PubMed ID: 25701228)
21. High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer.
Weidemann SA; Sauer C; Luebke AM; Möller-Koop C; Steurer S; Hube-Magg C; Büscheck F; Höflmayer D; Tsourlakis MC; Clauditz TS; Simon R; Sauter G; Göbel C; Lebok P; Dum D; Fraune C; Kind S; Minner S; Izbicki J; Schlomm T; Huland H; Heinzer H; Burandt E; Haese A; Graefen M; Heumann A
BMC Cancer; 2019 Oct; 19(1):944. PubMed ID: 31606028
[TBL] [Abstract][Full Text] [Related]
22. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.
Krohn A; Diedler T; Burkhardt L; Mayer PS; De Silva C; Meyer-Kornblum M; Kötschau D; Tennstedt P; Huang J; Gerhäuser C; Mader M; Kurtz S; Sirma H; Saad F; Steuber T; Graefen M; Plass C; Sauter G; Simon R; Minner S; Schlomm T
Am J Pathol; 2012 Aug; 181(2):401-12. PubMed ID: 22705054
[TBL] [Abstract][Full Text] [Related]
23. Secreted Frizzled-Related Protein 4 (SFRP4) Is an Independent Prognostic Marker in Prostate Cancers Lacking TMPRSS2: ERG Fusions.
Bernreuther C; Daghigh F; Möller K; Hube-Magg C; Lennartz M; Lutz F; Rico SD; Fraune C; Dum D; Luebke AM; Eichenauer T; Möller-Koop C; Schlomm T; Wittmer C; Huland H; Heinzer H; Graefen M; Haese A; Burandt E; Tsourlakis MC; Clauditz TS; Höflmayer D; Izbicki JR; Simon R; Sauter G; Minner S; Steurer S; Meiners J
Pathol Oncol Res; 2020 Oct; 26(4):2709-2722. PubMed ID: 32677026
[TBL] [Abstract][Full Text] [Related]
24. High-Level γ-Glutamyl-Hydrolase (GGH) Expression is Linked to Poor Prognosis in ERG Negative Prostate Cancer.
Melling N; Rashed M; Schroeder C; Hube-Magg C; Kluth M; Lang D; Simon R; Möller-Koop C; Steurer S; Sauter G; Jacobsen F; Büscheck F; Wittmer C; Clauditz T; Krech T; Tsourlakis MC; Minner S; Huland H; Graefen M; Budäus L; Thederan I; Salomon G; Schlomm T; Wilczak W
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28146062
[TBL] [Abstract][Full Text] [Related]
25. Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer.
Leinonen KA; Tolonen TT; Bracken H; Stenman UH; Tammela TL; Saramäki OR; Visakorpi T
Clin Cancer Res; 2010 May; 16(10):2845-51. PubMed ID: 20442300
[TBL] [Abstract][Full Text] [Related]
26. TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer.
Steurer S; Mayer PS; Adam M; Krohn A; Koop C; Ospina-Klinck D; Tehrani AA; Simon R; Tennstedt P; Graefen M; Wittmer C; Brors B; Plass C; Korbel J; Weischenfeldt J; Sauter G; Huland H; Tsourlakis MC; Minner S; Schlomm T
Eur Urol; 2014 Dec; 66(6):978-81. PubMed ID: 25015038
[TBL] [Abstract][Full Text] [Related]
27. FOXA1 expression is a strong independent predictor of early PSA recurrence in ERG negative prostate cancers treated by radical prostatectomy.
Tsourlakis MC; Eleftheriadou A; Stender A; Weigand P; Grupp K; Hube-Magg C; Kluth M; Schroeder C; Steurer S; Hinsch A; Luebke A; Angerer A; Wittmer C; Friedrich E; Göbel C; Büscheck F; Heinzer H; Graefen M; Simon R; Sauter G; Wilczak W; Minner S; Schlomm T; Jacobsen F
Carcinogenesis; 2017 Dec; 38(12):1180-1187. PubMed ID: 29029032
[TBL] [Abstract][Full Text] [Related]
28. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis.
Saramäki OR; Harjula AE; Martikainen PM; Vessella RL; Tammela TL; Visakorpi T
Clin Cancer Res; 2008 Jun; 14(11):3395-400. PubMed ID: 18519769
[TBL] [Abstract][Full Text] [Related]
29. Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate Cancers.
Burdelski C; Bujupi E; Tsourlakis MC; Hube-Magg C; Kluth M; Melling N; Lebok P; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Simon R; Schlomm T; Steurer S; Krech T
PLoS One; 2015; 10(6):e0128525. PubMed ID: 26030748
[TBL] [Abstract][Full Text] [Related]
30. Prevalence and prognostic significance of TMPRSS2-ERG gene fusion in lymph node positive prostate cancers.
Fleischmann A; Saramäki OR; Zlobec I; Rotzer D; Genitsch V; Seiler R; Visakorpi T; Thalmann GN
Prostate; 2014 Dec; 74(16):1647-54. PubMed ID: 25252136
[TBL] [Abstract][Full Text] [Related]
31. Apurinic/apyrimidinic endonuclease 1 (APE1/Ref-1) overexpression is an independent prognostic marker in prostate cancer without TMPRSS2:ERG fusion.
Juhnke M; Heumann A; Chirico V; Höflmayer D; Menz A; Hinsch A; Hube-Magg C; Kluth M; Lang DS; Möller-Koop C; Sauter G; Simon R; Beyer B; Pompe R; Thederan I; Schlomm T; Luebke AM
Mol Carcinog; 2017 Sep; 56(9):2135-2145. PubMed ID: 28467610
[TBL] [Abstract][Full Text] [Related]
32. High CHK2 protein expression is a strong and independent prognostic feature in ERG negative prostate cancer.
Eichenauer T; Federlein F; Möller K; Chirico V; Kind S; Lennartz M; Lutz F; Hube-Magg C; Höflmayer D; Fisch M; Huland H; Heinzer H; Graefen M; Haese A; Schroeder C; Lebok P; Minner S; Simon R; Sauter G; Schlomm T; Wilczak W; Steurer S; Luebke AM
Pathology; 2020 Jun; 52(4):421-430. PubMed ID: 32317175
[TBL] [Abstract][Full Text] [Related]
33. p16 upregulation is linked to poor prognosis in ERG negative prostate cancer.
Burdelski C; Dieckmann T; Heumann A; Hube-Magg C; Kluth M; Beyer B; Steuber T; Pompe R; Graefen M; Simon R; Minner S; Tsourlakis MC; Koop C; Izbicki J; Sauter G; Krech T; Schlomm T; Wilczak W; Lebok P
Tumour Biol; 2016 Sep; 37(9):12655-12663. PubMed ID: 27444279
[TBL] [Abstract][Full Text] [Related]
34. Upregulation of the heterogeneous nuclear ribonucleoprotein hnRNPA1 is an independent predictor of early biochemical recurrence in TMPRSS2:ERG fusion-negative prostate cancers.
Möller K; Wecker AL; Höflmayer D; Fraune C; Makrypidi-Fraune G; Hube-Magg C; Kluth M; Steurer S; Clauditz TS; Wilczak W; Simon R; Sauter G; Huland H; Heinzer H; Haese A; Schlomm T; Weidemann S; Luebke AM; Minner S; Bernreuther C; Bonk S; Marx A
Virchows Arch; 2020 Nov; 477(5):625-636. PubMed ID: 32417965
[TBL] [Abstract][Full Text] [Related]
35. Cytoplasmic Accumulation of Sequestosome 1 (p62) Is a Predictor of Biochemical Recurrence, Rapid Tumor Cell Proliferation, and Genomic Instability in Prostate Cancer.
Burdelski C; Reiswich V; Hube-Magg C; Kluth M; Minner S; Koop C; Graefen M; Heinzer H; Tsourlakis MC; Wittmer C; Huland H; Simon R; Schlomm T; Sauter G; Steurer S
Clin Cancer Res; 2015 Aug; 21(15):3471-9. PubMed ID: 25925890
[TBL] [Abstract][Full Text] [Related]
36. TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair.
Dal Pra A; Lalonde E; Sykes J; Warde F; Ishkanian A; Meng A; Maloff C; Srigley J; Joshua AM; Petrovics G; van der Kwast T; Evans A; Milosevic M; Saad F; Collins C; Squire J; Lam W; Bismar TA; Boutros PC; Bristow RG
Clin Cancer Res; 2013 Sep; 19(18):5202-9. PubMed ID: 23918607
[TBL] [Abstract][Full Text] [Related]
37. [TMPRSS2-ERG gene fusion in metastatic prostate cancers: a study of fine needle aspiration specimens].
Xiao L; Zhu XZ; Wang Y; Gong Y; Guo CC
Zhonghua Bing Li Xue Za Zhi; 2011 Jun; 40(6):392-6. PubMed ID: 21914348
[TBL] [Abstract][Full Text] [Related]
38. Cysteine-rich secretory protein 3 overexpression is linked to a subset of PTEN-deleted ERG fusion-positive prostate cancers with early biochemical recurrence.
Grupp K; Kohl S; Sirma H; Simon R; Steurer S; Becker A; Adam M; Izbicki J; Sauter G; Minner S; Schlomm T; Tsourlakis MC
Mod Pathol; 2013 May; 26(5):733-42. PubMed ID: 23196798
[TBL] [Abstract][Full Text] [Related]
39. Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer.
Wilczak W; Rashed S; Hube-Magg C; Kluth M; Simon R; Büscheck F; Clauditz TS; Grupp K; Minner S; Tsourlakis MC; Möller-Koop C; Graefen M; Adam M; Haese A; Wittmer C; Sauter G; Izbicki JR; Huland H; Schlomm T; Steurer S; Krech T; Lebok P
Carcinogenesis; 2017 Jan; 38(1):19-27. PubMed ID: 27803051
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer.
Hermans KG; Boormans JL; Gasi D; van Leenders GJ; Jenster G; Verhagen PC; Trapman J
Clin Cancer Res; 2009 Oct; 15(20):6398-403. PubMed ID: 19825963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
